Complete guides, comparisons and scientific analyses on peptides in skincare, health and biohacking.
Nasal absorption, the nose-to-brain question, and how the intranasal route compares with injection and oral peptides, peptide by peptide.
Tirzepatide became the first medicine approved for obstructive sleep apnea in adults with obesity. Here is what the SURMOUNT-OSA trials measured, what the semaglutide data add, and where the evidence stops.
A neutral look at kisspeptin, gonadorelin, hCG and growth hormone secretagogues, what human studies report, and why none of them replaces a proper medical workup for low testosterone.
Sheet, hydrogel and overnight collagen jelly masks explained: the molecular size problem, the film-forming and humectant effects that are real, and how collagen differs from collagen peptides and signal peptides like Matrixyl.
Semaglutide and tirzepatide trials recorded alopecia in a minority of participants. Here is what the published data say about how often it happens, why it may happen, and how much remains unknown.
Dulaglutide (Eli Lilly) and semaglutide (Novo Nordisk) are both weekly GLP-1 receptor agonists, but they are built differently and carry different outcome trial portfolios. Here is the published evidence, side by side.
Two very different pharmacological strategies: replacing growth hormone directly, or asking the pituitary to release more of its own. Here is what the published evidence, the regulatory labels and the anti-doping rules actually say.
Tirzepatide is the active ingredient in both products. What separates them is the approved indication, the regulatory file behind it, and how each one is supplied and paid for.
Human physiology has GLP-1 and GLP-2. It has no GLP-3. The label belongs to vendor catalogs, and the vial almost always contains retatrutide, an investigational triple receptor agonist from Eli Lilly.
One is a chemically synthesized small molecule, the other is a peptide carried across the stomach wall by an absorption enhancer. Here is what that difference changes in the evidence, the daily routine and the regulatory record.
The pre-filled BPC-157 pen, which has not been offered since November 2026, compared with the vial, and the alternatives available
The pre-filled copper peptide pen compared with the lyophilised vial, with prices checked on 12 November 2026